【投融资动态】玄言生物Pre-A轮融资，投资方为德同资本

Group 1 - The core viewpoint of the news is that Shanghai XuanYan Biotechnology Co., Ltd. has completed a Pre-A round of financing, with the amount undisclosed, and the investment was participated by DeTong Capital [1] Group 2 - XuanYan Biotechnology was established in April 2021 and focuses on creating AI drugs, early screening, and auxiliary diagnostic platforms to address unmet medical needs [2] - The company has developed an AI drug target discovery platform that utilizes clinical real patient samples collected from over twenty top-tier hospitals, combined with proprietary AI algorithms and bioinformatics analysis techniques [2] - XuanYan aims to establish an integrated precision medicine platform to address clinical needs in early screening, diagnosis, process management, and treatment of complex diseases such as cancer, critical illnesses, and cardiovascular diseases [2]